Lovastatin Patent Expiration
Lovastatin is Used for decreasing A-beta production in patients at risk of or exhibiting symptoms of Alzheimer's disease. It was first introduced by Merck Research Laboratories Div Merck Co Inc
Lovastatin Patents
Given below is the list of patents protecting Lovastatin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Altoprev | US6080778 | Methods for decreasing beta amyloid protein |
Mar 23, 2018
(Expired) | Azurity |
| Altoprev | US5916595 | HMG co-reductase inhibitor |
Dec 12, 2017
(Expired) | Azurity |
| Altoprev | US6485748 | Once daily pharmaceutical tablet having a unitary core |
Dec 12, 2017
(Expired) | Azurity |
Lovastatin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Lovastatin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Trastuzumab Deruxtecan and Lovastatin in HER2-low and Ultralow Advanced or Metastatic Breast Cancer | Washington University School of Medicine | NA |
NOT YET RECRUITING
(Sep 1, 2026)
| PHASE2 |